Needham & Company LLC Reaffirms “Buy” Rating for Immuneering (NASDAQ:IMRX)

Needham & Company LLC reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX) in a report issued on Friday morning,Benzinga reports. Needham & Company LLC currently has a $12.00 price objective on the stock.

IMRX has been the topic of a number of other reports. Chardan Capital restated a “buy” rating and issued a $13.00 price target on shares of Immuneering in a research report on Wednesday, January 8th. Morgan Stanley cut shares of Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th.

Immuneering Stock Up 9.1 %

NASDAQ:IMRX opened at $1.80 on Friday. The company has a market cap of $55.89 million, a PE ratio of -0.91 and a beta of -0.32. The business’s 50 day moving average is $1.79 and its two-hundred day moving average is $2.00. Immuneering has a 52 week low of $1.00 and a 52 week high of $3.83.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.16). As a group, sell-side analysts expect that Immuneering will post -1.86 EPS for the current fiscal year.

Institutional Trading of Immuneering

A number of large investors have recently modified their holdings of IMRX. Rockefeller Capital Management L.P. acquired a new position in Immuneering during the 4th quarter valued at about $390,000. First Manhattan CO. LLC. bought a new stake in shares of Immuneering during the fourth quarter valued at approximately $71,000. Bridgeway Capital Management LLC boosted its position in shares of Immuneering by 77.4% during the fourth quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company’s stock worth $113,000 after buying an additional 22,400 shares during the period. Marshall Wace LLP bought a new position in Immuneering in the 4th quarter worth approximately $47,000. Finally, XTX Topco Ltd increased its position in Immuneering by 177.2% in the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock valued at $72,000 after acquiring an additional 20,871 shares during the period. Institutional investors and hedge funds own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.